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Background: Aminoglycosides are mandatory in the treatment of severe infections in burns.
However, their pharmacokinetics are difficult to predict in critically ill patients. Our
objective was to describe the pharmacokinetic parameters of high doses of tobramycin
administered at extended intervals in severely burned patients.
Methods: We prospectively enrolled 23 burned patients receiving tobramycin in combina-
tion therapy for Pseudomonas species infections in a burn ICU over 2 years in a therapeutic
drugmonitoring program. Trough and post peak tobramycin levels weremeasured to adjust
drug dosage. Pharmacokinetic parameters were derived from two points first order kinetics.
Results: Tobramycin peak concentration was 7.4 (3.1–19.6) mg/ml and Cmax/MIC ratio 14.8
(2.8–39.2). Half-life was 6.9 (range 1.8–24.6) h with a distribution volume of 0.4 (0.2–1.0) l/kg.
Clearance was 35 (14–121) ml/min and was weakly but significantly correlated with crea-
tinine clearance.
Conclusion: Tobramycin had a normal clearance, but an increased volume of distribution
and a prolonged half-life in burned patients. However, the pharmacokinetic parameters of
tobramycin are highly variable in burned patients. These data support extended interval
administration and strongly suggest that aminoglycosides should only be used within a
structured pharmacokinetic monitoring program.
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The pharmacokinetic of many drugs is profoundly altered in
burned patients with modifications in both volumes of
distribution and drug disposal [1]. The immediate period after
burn is characterized by decreased cardiac output and hepatic
and renal drug clearances. This phase is followed by an acute
physiological response including an intense hypermetabolic
phase with the supranormal cardiac output, increased liver
and renal perfusion and – usually – increased drug clearances.* Corresponding author at: Department of Anesthesia, McGill Universi
Room D 10-145-3, Montreal H3G 1A4, Canada. Tel.: +1 514 934 1934x4
E-mail address: David.Bracco@McGill.Ca (D. Bracco).
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doi:10.1016/j.burns.2007.11.003These physiologic reactions make dosing antibiotics in
burned patients delicate [1]. In addition, previous exposure to
antibiotics and increasingly resistant micro-organisms made
the choice of the antibiotic and administration regimen
crucial. Aminoglycoside treatment remains mandatory for
difficult to treat organisms such as Pseudomonas species.
The antibacterial activity of aminoglycosides is strongly
dependent on the peak serum level. To achieve clinical success
a high peak serum levels tominimum inhibitory concentration
(MIC) ratios as well as high area under the curve to MIC (AUC)
are necessary [2,3]. Maximal serum concentrations toMIC ratioty Health Center, Montreal General Hospital, 1650 Cedar Avenue,
3030; fax: +1 514 934 8249.
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are also characterized by a prolonged post-antibiotic effect,
defined as a delayed regrowth of bacteria following exposure to
an antibiotic despite serum concentrations decreasing below
the MIC. The duration of this post-antibiotic effect against
gram-negative bacteria ranges from 1 to 4 h. The nephrotoxi-
city of aminoglycosides is mostly related to high trough
concentrations and interval between doses. This has brought
the concept of giving aminoglycosides at high doses at
extended intervals. Numerous clinical studies validated this
approach in non-burn patients and several meta-analyses
confirm its value. Despite good level of evidence, reported
clinical experience in critically ill and burn patients is
disappointing [4–8].
The aimsof this observational studywere (1) to describe the
pharmacokinetic parameters of extended interval dosing (EID)
tobramycin in burned patients enrolled in a therapeutic drug
monitoring (TDM)programand (2) to explore the determinants
of pharmacokinetic parameters in severely burned patients.2. Material and methods
TheMontreal Burn Centre is a 10 bed burn ICU serving an area
of 8 million inhabitants and admitting approximately 150
major burns each year (mean burn surface area: 22%). The
ethical committee of the hospital approved the study.
Informed consent from the patient or relative was waived
since this study was considered as clinical performance
improvement (Protocol #HD 04.087).
Between 1st July 2004 and 30th June 2006, patients inwhom
a combination treatment including an aminoglycoside was
required for nosocomial infections were prospectively
enrolled. Extended interval dosage was recommended. If
the dose of tobramycin was above 200 mg, it was infused over
1 h and in 30 min otherwise. Antibiotic drug concentrationsTable 1 – Demographic data
Gender
Age (years)
Weight on the TDM day (kg)
Burn surface area (%)
Surgical burned area (%)
Cause of injury
Associated inhalation injury
Delay from burns (days)
Mechanical ventilation
Tobramycin dose (mg)
Administration interval (h)
Plasma creatinine level (mmol/l)
Plasma albumin level (g/l)
Estimated creatinine clearance (ml/min)
Microorganisms requiring combined therapy
Infected site: n (%)
a 1 case, presumably from a burn wound infection.were performed routinely after the 3rd dose and dosages
adapted to optimize peak and trough levels. The distribution
half-life (T1/2 a) of tobramycin is between 0.36 and 0.5 h. Peak
levels drawn 30 min after infusion termination reflects this
distribution phase and thus a one compartmentmodelmay be
inadequate. To avoid this problem and focus on the true
elimination phase, peak levels were drawn 2 h after infusion
end. Trough levels were drawn just before the next dose.
Serum tobramycin level were measured by Fluorescence
Polarization Immunoassay [9] (Abbott TDX, Abbott Labora-
tories. Abbott Park, Illinois, USA).
The admission and actual body weight, plasma levels of
creatinine and albumin on the day of TDM assessment were
also recorded allowing estimation of the creatinine clearance
using the Cockroft–Gault equation.
Drug levelswere analyzed using a custommade plug-in (4D
view language; version 2003.5, ACI) part of our clinical
information database. The pharmacokinetic model is based
on a first order one compartment kinetic. Elimination rate
constant, plasma half-life, clearance, maximal (Cmax) and
minimal (Cmin) concentrations, AUC, Cmax/MIC ratio and
volume of distribution were calculated using the equations
described in the appendix. Based on these parameters the
optimal dosage and interval were calculated to achieve a peak
concentration of 8 mg/l and levels below the MIC at 4 h (post-
antibiotic effect). With an MIC of 0.5 mg/ml for tobramycin-
sensitive micro-organisms, this would provide a Cmax to MIC
ratio of above 16.
The plasma tobramycin concentration over time of a
standard 5 mg/kg once daily dose [10] administered to all burn
patients was calculated in each patient.
Data were analyzed using the SAS statistical platform. Due
to the reduced sample size, non-parametric tests were applied
and the population data are presented as median and range.
Maximal concentration (Cmax), clearance, and volumes of
distribution of tobramycin were compared with valuesProportions or median (range)
10 F/13 M
61 (19–77)
63.4 (41.6–101.9)
53 (10–70)
48 (10–70)
Thermal burn: 91%
Electrical burn: 9%
10/23 (43%)
33 (8–87)
14/23 (61%)
260 (80–350)
24 (18–36)
57 (29–116)
27 (14–38)
96.1 (38.8–261.9)
Pseudomonas aeruginosa 96%
Stenotrophomonas maltophilia 4%
Skin: 19 (83%)
Lung: 3 (13%)
Bloodstream infection: 1 (4%)a
Fig. 1 – Measured tobramycin levels.
Fig. 2 – Correlation between creatinine and tobramycin
clearances.
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test. Observed and simulated serum tobramycin concentra-
tion were plotted against time by running each patient’s
observed and simulated concentrations with a 1 min step.
Pharmacokinetic parameters were explored against popula-
tion descriptors by univariate analysis. Due to reduced sample
size no multivariate analysis was performed. A P value lower
than 0.05 was considered significant.3. Results
During the 2 years period a total of 287 patients were seen in
the burn unit. A total of 23 patients receiving tobramycin were
included in the TDM program over 2 years. The characteristics
of these patients are presented in Table 1. No patient had
hepatic failure or required extra-corporeal renal support.Table 2 – Pharmacokinetic data
Median (range)
Measured through tobramycin level (mg/l) 1.0 (0.2–4.4)
Measured 2 h post administration level (mg/l) 6.3 (2.1–14.6)
Elimination half-life (h) 6.9 (1.8–24.6)
Tobramycin clearance (ml/min) 35.3 (14.3–120.9)
(% of creatinine clearance) 38 (10–110)
Calculated Cmax (mg/l) 7.4 (3.1–19.6)
Cmax/CMI ratio 14.8 (2.8–39.2)
Calculated time to MIC (h) 26.1 (5.9–99.3)
Post antibiotic effect
Through level above MIC 15/23
Through level below MIC 7/23
Time below MIC (in 7/23 patients) (h) 4.8 (0.7–10.1)
Cmax to MIC ratio 14.8 (2.8–39.2)
Distribution volume (l) 26.5 (11.7–54.3)
Distribution volume (l/kg) 0.4 (0.2–1.0)
AUC (mg/l*h) 86.6 (11.8–161.1)
Optimal dose (mg) 260 (113–525)
Optimal dose (mg/kg) 3.8 (2.3–9.2)
Optimal dosing interval (h) 36 (9.5–120)Tobramycin daily dose ranged from 80 to 350 mg with
intervals from 16 to 36 h. Trough and peak concentrations of
tobramycin are shown in Table 2. There was a great variation
of peak plasma concentration and volumes of distribution
(Fig. 1). Only 35% (8/23) had peak serum levels that were in the
optimal range (grey box), peak levels were below in 39% (9/23)
andwere above the optimal range in 26% (6/23 of the patients).
In 70% (16/23) of patients, the tobramycin plasma level
remained above 0.5 mg/l at all times. Time below CMI was
between 40 min and 10 h in the remaining seven patients. The
median tobramycin clearance was found to be 38% of the
median creatinine clearance (Fig. 2). There was a weak but
significant correlation between tobramycin and creatinine
clearances. No patient developed renal failure, and the plasma
creatinine levels were not modified by tobramycin adminis-
tration. Decreasing plasma levels of albumin correlatedwith aFig. 3 – Correlation between plasma albumin level and
tobramycin half-life.
Fig. 4 – Tobramycin clearance and days post-burn.
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expressed as a proportion of creatinine clearance – showed an
inverse relationship with the post-burn delay (Fig. 4).
There was no correlation between the volume of distribu-
tion and the day after burn, fluid accumulation, burn surface
area, creatinine or albumin plasma levels.
To reach a target Cmax of 8 mg/ml and 4 h below theMIC, the
median optimal dose would be 260 mg (range 113–525 mg) or
3.8 mg/kg (range 2.3–9.2 mg/kg). A median administration
interval of 36 h (range 9.5–120 h) would be required.
The extrapolated time course of plasma tobramycin
concentrations following a ‘‘flat rate’’ of 5 mg/kg of tobramy-
cin every 24 h showed a wide variation in peak and through
levels (Fig. 5). Only 48% (11/23) peak plasma levels were in the
suggested therapeutic target, 48% (11/23) peak levels being
above the optimal target and one was insufficient.4. Discussion
Extended interval aminoglycosides regimens are progres-
sively accepted as the preferred administration schedule inFig. 5 – Extrapolated plasma tobramycin levels following a
standard 5 mg/kg Q24 h regimen in a burn population.critically ill patients. However, there is little information on
the pharmacokinetic of extended interval administration of
aminoglycosides in burn patients [8]. The main findings of the
present study were an important increase in distribution
volume and in elimination half-life with a near normal
tobramycin clearance.
Tobramycin binding to protein is below 30% [12]. Low
plasma albumin levels may interfere with pharmacodynamic
properties of aminoglycosides, although this has never been
demonstrated for tobramycin. We observed a prolongation of
thehalf-life and an increase in distribution volume, suggesting
a almost unchanged in clearance of tobramycin. Tobramycin
clearance was lower than previously reported in burned
patients receiving 5–7 mg/kg of gentamycin or tobramycin [8].
Aminoglycosides are filtered and partly reabsorbed in
proximal tubular cells [13]. This reabsorption mechanism
induces an accumulation of tobramycin in cortical renal cells,
contributing to its nephrotoxic effect. Tobramycin reabsorp-
tion is, in part, coupled with megalin which is a non specific
proximal tubular reabsorption molecule [14]. One may spec-
ulate that due to increased glomerular endothelial perme-
ability more tobramycin reaches the proximal tubule. The
megalin complex could be saturated and cannot reabsorb the
increased tubular load of aminoglycosides, increasing its
elimination.
Peris-Marti et al. [15] measured tobramycin pharmacoki-
netics in 51 critically ill patients and calculated the pharma-
cokinetic parameters. They found an adequate Cmax and Cmax
to MIC ratio but found an increased time belowMIC. This time
below MIC exceeded the duration of the post-antibiotic effect,
exposing to a risk of bacterial proliferation. Buijk et al. [16]
pooled the TDM data from ICU patients receiving gentamicin
(n = 66) or tobramycin (n = 23). The mean distribution volume
was 0.31 l/kg, with a clearance of 83 ml/min and an half-life of
4.0 h. They found a wide variability of aminoglycoside
pharmacokinetic in critically ill patients. Barletta et al.
investigated TDM of tobramycin in 19 critically ill patients
[5]. The mean observed distribution volume was 0.3 l/kg and
half-life 2.9 h. Dorman et al. [7] measured tobramycin and
gentamicin levels in 53 ICU patients. They also found an
increase in distribution volume suggesting that larger loading
doses may be required.
Recently Conil et al. [4] measured the pharmacokinetic
parameter of 20 mg/kg amikacin in 38 adult burn patients.
They showed that these burns requires higher than
normal doses, and also exhibit a large interindividual
variability. The present data confirm Conil’s investigation
showing that burn patients have an increased distribution
volume for aminoglycosides, and that the aminoglycoside
clearance is proportional to the creatinine clearance. Conil
[4] showed an inverse relationship between the burn surface
area and the aminoglycoside clearance mainly due to very
high clearance in less severe burns. As no patients with
BSA < 10% were included in our population we were
unable to show a relationship between BSA and tobramycin
clearance.
Hoey et al. [8] investigated single daily doses of aminoglyco-
sides (gentamicin or tobramycin) in 52 burned patient. They
found a wide variability of Cmax and time to MIC, and
concluded that burned patients were not good candidates
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high variability of tobramycin pharmacokinetic parameters
but showed that dosage and interval of administrationmay be
optimized with a strict TDM program.
The major limitations of the study were the small
number of patients, the wide variation of the administration
protocols and the clinical conditions of these patients.
The use of estimated value of creatinine clearance may limit
the value of comparison of tobramycin and creatinine
clearance. However, antibiotic doses were not adapted to
the creatinine clearance. The kinetic calculations were
based only on two points, and this may decrease the
precision of the model. Complete pharmacokinetic explora-
tion of aminoglycosides includes three compartments: (1) A
rapid initial redistribution compartment with a half-life of
0.36–0.5 h. (2) A true elimination phase explored in the
present study and (3) A so-called ‘‘deep’’ compartment
reflecting tissue fixation with a half-life of 200 h [17]. We
hypothesized that the contribution of this ‘‘deep’’ compart-
ment was negligeable in the present study. Patients were
enrolled from 8 to 87 days after major burn. Although they
had a variable post-burn time, they all shared a severe sepsis
with multi-resistant organisms.5. Conclusions
The pharmacokinetic of tobramycin is difficult to predict in
critically burned patients. The increased volume of distribu-
tion leads to suboptimal Cmax and Cmax/MIC ratio, whereas
prolonged elimination half-life exposes the patient to high
through concentration and increased risk of oto- and
nephrotoxicity. Our data shows that close therapeutic drug
monitoring is strongly suggested for tobramycin use in
severely burned patients to optimize the Cmax/MIC ratio and
the duration at low concentration. In this context, these drugs
remain an excellent choice in difficult to treat burn infections.Conflict of interest statement
None.Appendix A. Pharmacokinetic equations used
Elimination slope
l ¼ lnðconcmeasured residual=concmeasured post-doseÞ
DTimeðpost-dose! residualÞ
Elimination half-life
T1=2 ¼ 0:693
l
Maximal concentration
Concmax ¼
concmeasuredpost-dose
elDTimeðend infusion!post-samplingÞConcentration function
Conctime i ¼ concmax  elDTimeðEnd infusion!Time iÞ
Residual concentration
Concresid ¼ concmax  elDTimeðend infusion! startnext infusionÞ
Volume of distribution
Volume of distribution
¼ perfusion speed½mg=h  ð1 e
lperfusion durationÞ
l ðCmax  Cmin  eðlperfusion durationÞÞ
Tobramycin clearance
Clearance ¼ 0:693 distribution volume
elimination half-life
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